Safety and Efficacy of Human Muse Cell-Based Product for Acute Myocardial Infarction in a First-in-Human Trial

Background:Because ST-elevation myocardial infarction (STEMI) extensively damages the heart, regenerative therapy with pluripotent stem cells such as multilineage-differentiating stress enduring (Muse) cells is required.Methods and Results:In a first-in-human study, 3 STEMI patients with a left vent...

Full description

Saved in:
Bibliographic Details
Published in:Circulation Journal 2020/06/25, Vol.84(7), pp.1189-1192
Main Authors: Noda, Toshiyuki, Nishigaki, Kazuhiko, Minatoguchi, Shinya
Format: Article
Language:English
Subjects:
Acute myocardial infarction
Aged
Cell Lineage
Female
Humans
Male
Middle Aged
Muse cell-based product
Myocardium - pathology
Phenotype
Pluripotent Stem Cells - metabolism
Pluripotent Stem Cells - transplantation
Recovery of Function
Regeneration
Safety
ST Elevation Myocardial Infarction - pathology
ST Elevation Myocardial Infarction - physiopathology
ST Elevation Myocardial Infarction - surgery
Stroke Volume
Time Factors
Treatment Outcome
Ventricular Function, Left
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background:Because ST-elevation myocardial infarction (STEMI) extensively damages the heart, regenerative therapy with pluripotent stem cells such as multilineage-differentiating stress enduring (Muse) cells is required.Methods and Results:In a first-in-human study, 3 STEMI patients with a left ventricular ejection fraction (LVEF) ≤45% after successful percutaneous coronary intervention received intravenously 1.5×107cells of a human Muse cell-based product, CL2020. The safety and efficacy on LVEF and wall motion score index (WMSI) were evaluated for 12 weeks. No adverse drug reaction was noted. LVEF and WMSI were markedly improved.Conclusions:The first-in-human intravenous administration of CL2020 was safe and markedly improved LV function in STEMI patients.
ISSN:1346-9843
1347-4820
1347-4820
DOI:10.1253/circj.CJ-20-0307